Literature DB >> 32398784

Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients.

Mohamad Mohty1, Domenico Russo2, Nicola Polverelli3, Paolo Tura2,1, Giorgia Battipaglia1, Michele Malagola2, Simona Bernardi2,4, Lisa Gandolfi2, Tatiana Zollner2, Camilla Zanaglio2,4, Mirko Farina2, Enrico Morello2, Alessandro Turra2.   

Abstract

Nowadays, the evaluation of elderly patients' eligibility for allogeneic stem cell transplantation (allo-SCT) is crucial. We evaluated the feasibility and efficacy of a multidimensional geriatric assessment, the Fondazione Italiana Linfomi (FIL) score, on a cohort of 228 patients older than 60 years submitted to allo-SCT in Italy and France from 2008 to 2018. Based on FIL score, available in 215 patients, 125 (58%) patients were classified as "fit" and 90 as "unfit/frail." The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was measured in 222 patients (97%); 71 (32%) patients had HCT-CI 0, 75 (34%) patients scored 1-2, and 76 (34%) ≥3. A total of 121 (53%) patients died after a median follow-up of 36 months. FIL score was found to highly predict survival, due to an excess of NRM in unfit/frail group, and confirmed its independent prognostic role on OS (HR: 0.37; 95% CI: 0.25-0.55; p < 0.0001). On the contrary, the HCI-CI failed in allo-SCT outcome prediction (HR: 1.06; 95% CI: 0.96-1.16; p = 0.27). In summary, a comprehensive geriatric assessment with FIL score seems to add significant prognostic information in elderly patients submitted to allo-SCT. The pretransplant adoption of this easy-to-use tool could help the patients' selection and management.

Entities:  

Mesh:

Year:  2020        PMID: 32398784     DOI: 10.1038/s41409-020-0934-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  29 in total

1.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Daniel A Pollyea; Masha Kocherginsky; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Todd Zimmerman; Sonali Smith; Lucy Godley; Michael Thirman; Christopher Daugherty; Martine Extermann; Richard Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

2.  Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale.

Authors:  M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds
Journal:  Psychiatry Res       Date:  1992-03       Impact factor: 3.222

3.  Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.

Authors:  Lori S Muffly; Masha Kocherginsky; Wendy Stock; Quynh Chu; Michael R Bishop; Lucy A Godley; Justin Kline; Hongtao Liu; Olatoyosi M Odenike; Richard A Larson; Koen van Besien; Andrew S Artz
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

4.  Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Olle Ringdén; Ariane Boumendil; Myriam Labopin; Jonathan Canaani; Dietrich Beelen; Gerhard Ehninger; Dietger Niederwieser; Jurgen Finke; Matthias Stelljes; Armin Gerbitz; Arnold Ganser; Nicolaus Kröger; Lothar Kantz; Arne Brecht; Bipin Savani; Behnam Sadeghi; Mohamad Mohty; Arnon Nagler
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-07       Impact factor: 5.742

5.  Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients.

Authors:  Lori S Muffly; Melissa Boulukos; Kate Swanson; Masha Kocherginsky; Paula Del Cerro; Linda Schroeder; Lisa Pape; Martine Extermann; Koen Van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2012-11-15       Impact factor: 5.742

6.  Comprehensive geriatric assessment and its clinical impact in oncology.

Authors:  Jane Jijun Liu; Martine Extermann
Journal:  Clin Geriatr Med       Date:  2011-12-06       Impact factor: 3.076

7.  Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.

Authors:  G W Rewcastle; G J Atwell; B C Baguley; M Boyd; L L Thomsen; L Zhuang; W A Denny
Journal:  J Med Chem       Date:  1991-09       Impact factor: 7.446

8.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.

Authors:  Mohamed Sorror; Barry Storer; Brenda M Sandmaier; David G Maloney; Thomas R Chauncey; Amelia Langston; Richard T Maziarz; Michael Pulsipher; Peter A McSweeney; Rainer Storb
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

9.  A measure of primary sociobiological functions.

Authors:  S Katz; C A Akpom
Journal:  Int J Health Serv       Date:  1976       Impact factor: 1.663

10.  The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Authors:  Jakob R Passweg; Helen Baldomero; Grzegorz W Basak; Christian Chabannon; Selim Corbacioglu; Rafael Duarte; Jürgen Kuball; Arjan Lankester; Silvia Montoto; Régis Peffault de Latour; John A Snowden; Jan Styczynski; Ibrahim Yakoub-Agha; Mutlu Arat; Mohamad Mohty; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2019-02-06       Impact factor: 5.483

View more
  7 in total

1.  Allogeneic hematopoietic cell transplantation for older patients.

Authors:  Richard J Lin; Andrew S Artz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.

Authors:  Li-Wen Huang; Ying Sheng; Charalambos Andreadis; Aaron C Logan; Gabriel N Mannis; Catherine C Smith; Karin M L Gaensler; Thomas G Martin; Lloyd E Damon; Chiung-Yu Huang; Rebecca L Olin
Journal:  Transplant Cell Ther       Date:  2022-03-03

3.  Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.

Authors:  Joseph E Maakaron; Mei-Jie Zhang; Karen Chen; Sunil Abhyankar; Vijaya Raj Bhatt; Saurabh Chhabra; Najla El Jurdi; Sherif S Farag; Fiona He; Mark Juckett; Marcos de Lima; Navneet Majhail; Marjolein van der Poel; Ayman Saad; Bipin Savani; Celalettin Ustun; Edmund K Waller; Mark Litzow; Partow Kebriaei; Christopher S Hourigan; Wael Saber; Daniel Weisdorf
Journal:  Bone Marrow Transplant       Date:  2022-04-02       Impact factor: 5.174

4.  Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper.

Authors:  Hira S Mian; Shakira J Grant; Smith Giri; Mazie Tsang; Reena V Jayani
Journal:  J Geriatr Oncol       Date:  2020-01-31       Impact factor: 3.599

Review 5.  How old is too old for a transplant?

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2021-01-12       Impact factor: 3.020

6.  Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.

Authors:  Maxime Jullien; Corentin Orvain; Ana Berceanu; Marie-Anne Couturier; Thierry Guillaume; Pierre Peterlin; Alice Garnier; Amandine Le Bourgeois; Marion Klemencie; Aline Schmidt; Mathilde Hunault; Etienne Daguindau; Xavier Roussel; Pascal Delepine; Gaelle Guillerm; Aurelien Giltat; Sylvie François; Sylvain Thepot; Steven Le Gouill; Marie-C Béné; Patrice Chevallier
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

Review 7.  How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Authors:  Nicola Polverelli; Mirko Farina; Mariella D'Adda; Enrico Damiani; Luigi Grazioli; Alessandro Leoni; Michele Malagola; Simona Bernardi; Domenico Russo
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.